FDA letters track liquid supplement guidance
This article was originally published in The Tan Sheet
Executive Summary
Courtesy letters FDA's Division of Dietary Supplement Programs sent in 2010 appear to follow the agency's 2009 draft guidance on distinguishing liquid supplements from conventional foods (1"The Tan Sheet" Aug. 16, 2010). An April 22 2letter to Tahitian Noni International, posted on FDA's docket Aug. 24, says the Provo, Utah, firm's Tahitian Noni Original Bioactive Beverage products cannot make structure/function claims as long as they are promoted as beverages. A February 3letter to Next Generation Beverages of Hoboken, N.J., and a January 4letter to Nada Beverage Co. of Powder Springs, Ga., similarly preclude the firms' beverage products from making supplement claims. The letters are in response to the companies' notifications of supplement claims
You may also be interested in...
Supplement Firms Must Calculate Risk From Claims To Survive - Attorneys
Dietary supplement and functional food marketers should be cautious with health claims and ingredient safety if they want to avoid government scrutiny and remain profitable, according to a pair of food and drug attorneys
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.